Cardiac disease in pregnancy — preconception & risk stratification
Maternal cardiac risk · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Pre-existing cardiac disease is a leading cause of maternal mortality. Preconception counselling and the modified WHO classification stratify risk, guide the safety of pregnancy, and plan a multidisciplinary approach to medication, monitoring and delivery.
Red flags
- Severe pulmonary arterial hypertension (very high maternal mortality)
- Severe symptomatic left-heart obstruction (e.g. mitral/aortic stenosis)
- Marfan with aortic root >45 mm
- Systemic ventricular EF <30% or NYHA III-IV
- Prior peripartum cardiomyopathy with incomplete recovery
Assessment
Differential diagnosis
- Congenital heart disease (repaired/unrepaired)
- Valvular heart disease (especially mitral stenosis)
- Cardiomyopathy (including peripartum)
- Aortopathy (Marfan, bicuspid)
- Pulmonary arterial hypertension
- Ischaemic heart disease / arrhythmia
Investigations
- Transthoracic echo for structure and function
- ECG and ambulatory monitoring if arrhythmia
- Aortic imaging (MRI) in aortopathy
- Functional capacity assessment
- NT-proBNP as a baseline
- Review of current cardiac medications for teratogenicity
Management
- Offer preconception counselling to all women with known cardiac disease
- Apply the modified WHO (mWHO) classification to estimate maternal risk
- Advise against pregnancy in mWHO class IV conditions (e.g. severe PAH, severe systemic ventricular dysfunction, Marfan with dilated aorta)
- Review and switch teratogenic drugs (ACEi/ARB, warfarin, spironolactone) before conception
- Optimise cardiac lesions before pregnancy where feasible (e.g. valve intervention)
- Establish a pregnancy heart-team (cardiology, obstetrics, anaesthesia)
- Plan antenatal monitoring intensity by risk class
- Manage anticoagulation decisions in mechanical valves carefully across trimesters
- Make a documented delivery plan including mode and location of delivery
- Monitor for heart failure, arrhythmia and aortic events during pregnancy
- Plan postpartum monitoring, including for peripartum cardiomyopathy
- Advise on safe contraception
Drugs & doses
Labetalol 100-400 mg PO BD/TDS (pregnancy-safe antihypertensive)
Bisoprolol/metoprolol as pregnancy-compatible beta-blocker for arrhythmia/HF
Low-molecular-weight heparin for anticoagulation (mechanical valve regimens individualised)
Avoid ACEi, ARB, spironolactone and (in early pregnancy) warfarin
Hydralazine/nifedipine for blood pressure where needed
Disposition
Refer to a pregnancy heart-team / specialist obstetric cardiology service; preconception counselling and documented delivery planning.
Complications & pitfalls
- Maternal heart failure
- Arrhythmia
- Aortic dissection
- Thromboembolism (especially mechanical valves)
- Fetal growth restriction and prematurity
Exam pearls
- mWHO class IV conditions warrant advice against pregnancy and discussion of termination if it occurs
- ACEi/ARB and spironolactone are contraindicated — switch before conception
- Mechanical valve anticoagulation in pregnancy requires specialist individualised planning
- Haemodynamic burden peaks in the third trimester and around delivery
- Severe pulmonary arterial hypertension carries extremely high maternal mortality
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.